Status:
RECRUITING
Predicting Psychotic Relapse Using Speech-Based Early Detection
Lead Sponsor:
Douglas Mental Health University Institute
Conditions:
Psychosis
Eligibility:
All Genders
16+ years
Brief Summary
Psychotic disorders, including schizophrenia and affective psychosis, are severe mental health conditions marked by recurrent episodes that contribute to long-term disability. Relapses, characterized ...
Detailed Description
OBJECTIVES: The primary goal of this study is to develop and validate a speech-based digital model to predict psychotic relapses in individuals with early psychosis. The study specifically aims to: T...
Eligibility Criteria
Inclusion
- Age must be 16 years and older
- Diagnosis must meet DSM-5 criteria for psychotic disorders, including schizophrenia, schizoaffective disorder, or related conditions
- Fluency in English or French
- Must be currently receiving treatment through an EPI program
Exclusion
- Severe comorbid speech or language disorders (e.g., aphasia)
- Primary diagnosis of non-psychotic disorders
- Inability to provide consent or complete assessments
Key Trial Info
Start Date :
May 27 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2029
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06978894
Start Date
May 27 2024
End Date
July 1 2029
Last Update
May 18 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Robarts Research Institute
London, Ontario, Canada, N6A 5B7
2
Douglas Mental Health University Institute
Montreal, Quebec, Canada, H4H 1A8
3
Vitam
Québec, Quebec, Canada, G1J 2G1